Table 3.

Key clinical trials of EphA2 targeted therapy in cancer

Agent or approaches	Trial identifier	Study characteristics	Intervention	Status
MEDI-547	NCT00796055	Phase 1, n = 6 EphA2-positive solid tumor	IV infusion with MEDI-547 0.08 mg/kg on day 1 of 21-day cycle Primary outcome: safety and tolerability	Terminated
DS-8895a	NCT02252211	Phase 1, n = 9 EphA2-positive solid tumor	Infusion with ^89Zr-Df-DS-8895a 0.2 mg/kg i.v on day 1. DS-8895a 1, 3, or 10 mg/kg on days 8 and 22, and ^89Zr-Df-DS-8895a 1, 3, or 10 mg/kg on day 36 Primary outcome: toxicity	Completed
DS-8895a	NCT02004717	Phase 1, n = 37 Solid tumor	Step 1: IV infusion with DS-8895a 0.1, 0.3, 1, 5, 10, or 20 mg/kg on day 1 of 14-day cycle; step 2: IV infusion with DS-8895a 20 mg/kg on day 1 of 14-day cycle Primary outcome: toxicity, serum pharmacokinetics	Completed
CAR-T cell	NCT02575261	Phase 1/2, n = 60 EphA2-positive glioma	Primary outcome: effectiveness	Completed
CAR-T cell	NCT03423992	Phase 1, n = 100 Recurrent glioma	Primary outcome: adverse events	Ongoing
BT5528	NCT04180371	Phase 1/2, n = 152 Solid tumor	IV infusion of BT5528 once a week (days 1, 8, 15, and 22) on a 4-week cycle with or without 480 mg nivolumab Primary outcome: safety, MDT	Ongoing
SiRNA-EphA2-DOPC	NCT01591356	Phase 1, n = 40 Advanced solid tumor	IV infusion of siRNA-EphA2-DOPC on days 1 and 4 of 21-day cycle Primary outcome: safety, MDT, and ORR	Ongoing
MM-310	NCT03076372	Phase 1, n = 34 Solid tumor	IV infusion of MM-310 on day 1 of 21-day cycle Primary outcome: MDT	Ongoing
Vaccine	NCT02754362	Phase 2, n = 30 Recurrent glioblastoma	Block 1: bevacizumab every 2 weeks for 2 doses; block 2: vaccine + poly-ICLC + bevacizumab on weeks 1, 3, 5, and 7; block 3: vaccine + poly-ICLC monthly and bevacizumab every 2 weeks for 10 months Primary outcome: immune response, tumor response	Active, not recruiting